» Articles » PMID: 19703435

Ultrasound, Liposomes, and Drug Delivery: Principles for Using Ultrasound to Control the Release of Drugs from Liposomes

Overview
Specialty Biochemistry
Date 2009 Aug 26
PMID 19703435
Citations 105
Authors
Affiliations
Soon will be listed here.
Abstract

Ultrasound is used in many medical applications, such as imaging, blood flow analysis, dentistry, liposuction, tumor and fibroid ablation, and kidney stone disruption. In the past, low frequency ultrasound (LFUS) was the main method to downsize multilamellar (micron range) vesicles into small (nano scale) unilamellar vesicles. Recently, the ability of ultrasound to induce localized and controlled drug release from liposomes, utilizing thermal and/or mechanical effects, has been shown. This review, deals with the interaction of ultrasound with liposomes, focusing mainly on the mechanical mechanism of drug release from liposomes using LFUS. The effects of liposome lipid composition and physicochemical properties, on one hand, and of LFUS parameters, on the other, on liposomal drug release, are addressed. Acoustic cavitation, in which gas bubbles oscillate and collapse in the medium, thereby introducing intense mechanical strains, increases release substantially. We suggest that the mechanism of release may involve formation and collapse of small gas nuclei in the hydrophobic region of the lipid bilayer during exposure to LFUS, thereby inducing the formation of transient pores through which drugs are released. Introducing PEG-lipopolymers to the liposome bilayer enhances responsivity to LFUS, most likely due to absorption of ultrasonic energy by the highly hydrated PEG headgroups. The presence of amphiphiles, such as phospholipids with unsaturated acyl chains, which destabilize the lipid bilayer, also increases liposome susceptibility to LFUS. Application of these principles to design highly LFUS-responsive liposomes is discussed.

Citing Articles

Targeted nanoliposomes for precision rheumatoid arthritis therapy: a review on mechanisms and potential.

Girase R, Gujarathi N, Sukhia A, Kota S, Patil T, Aher A Drug Deliv. 2025; 32(1):2459772.

PMID: 39891600 PMC: 11789225. DOI: 10.1080/10717544.2025.2459772.


Nanotheranostics for gynecological cancers: a path forward for Africa.

Aza M, Suberu A, Balogun M, Adegbola G, Sankoh M, Oyediran T Med Oncol. 2024; 42(1):34.

PMID: 39704911 DOI: 10.1007/s12032-024-02582-4.


Ultrasound-Activated Nanomaterials for Therapeutics.

Paris J, Vallet-Regi M Bull Chem Soc Jpn. 2024; 93(2):220-229.

PMID: 39650549 PMC: 7617089. DOI: 10.1246/bcsj.20190346.


Drug Release via Ultrasound-Activated Nanocarriers for Cancer Treatment: A Review.

Al Refaai K, AlSawaftah N, Abuwatfa W, Husseini G Pharmaceutics. 2024; 16(11).

PMID: 39598507 PMC: 11597164. DOI: 10.3390/pharmaceutics16111383.


Predicting Calcein Release from Ultrasound-Targeted Liposomes: A Comparative Analysis of Random Forest and Support Vector Machine.

Shomope I, Percival K, Abdel Jabbar N, Husseini G Technol Cancer Res Treat. 2024; 23:15330338241296725.

PMID: 39539114 PMC: 11561990. DOI: 10.1177/15330338241296725.